Liisa A. Bayko

JMP Securities’ Liisa A. Bayko believes Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)'s stock valuation is compelling at the current levels and reflect the HCV opportunity to a large extent. Bayko upgraded the rating on the company from Market Perform to Market Outperform, with a price...

The FDA has asked Sarepta Therapeutics Inc (NASDAQ: SRPT) to provide dystrophin data, as part of the ongoing evaluation of the eteplirsen NDA [New Drug Application]. JMP Securities’ Liisa A. Bayko reiterated a Market Underperform rating for the company, with a price target of $10. The FDA...

Shares of Enanta Pharmaceuticals Inc (NASDAQ: ENTA) have declined 51.37 percent over the past three months, hitting a low of $23.90 on Thursday. Liisa A. Bayko of JMP Securities has upgraded the rating on the company from Market Perform to Outperform, with a price target of $32. Bayko...

JMP Securities reviewed Q4 earnings for Raptor Pharmaceutical Corp. (NASDAQ: RPTP) on Wednesday and maintained a Market Outperform rating and $33 price target. Analyst Liisa A. Bayko expected revenue of $18.1 million and a loss per share of $0.31 for the company’s fourth quarter. For FY...

In a report published Tuesday, JMP Securities analyst Liisa A. Bayko reiterated a Market Outperform rating on Hyperion Therapeutics Inc (NASDAQ: HPTX), but lowered the price target from $40.00 to $35.00. In the report, JMP Securities noted, “Following a discovery of fraudulent activity concerning...

In a research note released Thursday, JMP analyst Liisa A. Bayko increased the price target on Intermune (NASDAQ: ITMN) from $48 to $55 and reiterated a Market Outperform rating. The analyst increased the price target based on a survey that JMP conducted, “Survey says…pirfenidone preferred product...

In Monday's JMP Securities Morning Note, analyst Liisa A. Bayko downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Market Outperform to Market Perform. Shares of Sarepta gained approximately 40% following Prosensa Holding N.V.'s (NASDAQ: RNA) announcement that will file approval for its drug...

In a report published Wednesday, JMP Securities analyst Liisa A. Bayko reiterated a Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX), and raised the price target from $5.00 to $8.00. In the report, JMP Securities noted, “Investors see BioCryst's oral kallikrein program as a...